SE9501671D0 - Method and composition for prevention of posterior capsule opacification - Google Patents
Method and composition for prevention of posterior capsule opacificationInfo
- Publication number
- SE9501671D0 SE9501671D0 SE9501671A SE9501671A SE9501671D0 SE 9501671 D0 SE9501671 D0 SE 9501671D0 SE 9501671 A SE9501671 A SE 9501671A SE 9501671 A SE9501671 A SE 9501671A SE 9501671 D0 SE9501671 D0 SE 9501671D0
- Authority
- SE
- Sweden
- Prior art keywords
- posterior capsule
- composition
- prevention
- capsule opacification
- surgery
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010036346 Posterior capsule opacification Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 238000001356 surgical procedure Methods 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9501671A SE9501671D0 (sv) | 1995-05-05 | 1995-05-05 | Method and composition for prevention of posterior capsule opacification |
| PCT/SE1996/000588 WO1996034629A1 (en) | 1995-05-05 | 1996-05-03 | Method and composition for prevention of posterior capsule opacification |
| DE69634080T DE69634080T2 (de) | 1995-05-05 | 1996-05-03 | Mittel zur verhinderung der truebung der vorderen linsenkapsel |
| AT96914498T ATE285252T1 (de) | 1995-05-05 | 1996-05-03 | Mittel zur verhinderung der truebung der vorderen linsenkapsel |
| JP8533247A JPH11504342A (ja) | 1995-05-05 | 1996-05-03 | 水晶体後嚢の不透明化を予防するための方法および組成物 |
| AU57840/96A AU5784096A (en) | 1995-05-05 | 1996-05-03 | Method and composition for prevention of posterior capsule opacification |
| EP96914498A EP0825877B1 (de) | 1995-05-05 | 1996-05-03 | Mittel zur verhinderung der truebung der vorderen linsenkapsel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9501671A SE9501671D0 (sv) | 1995-05-05 | 1995-05-05 | Method and composition for prevention of posterior capsule opacification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE9501671D0 true SE9501671D0 (sv) | 1995-05-05 |
Family
ID=20398207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9501671A SE9501671D0 (sv) | 1995-05-05 | 1995-05-05 | Method and composition for prevention of posterior capsule opacification |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0825877B1 (de) |
| JP (1) | JPH11504342A (de) |
| AT (1) | ATE285252T1 (de) |
| AU (1) | AU5784096A (de) |
| DE (1) | DE69634080T2 (de) |
| SE (1) | SE9501671D0 (de) |
| WO (1) | WO1996034629A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6491721B2 (en) | 1998-04-15 | 2002-12-10 | Alcon Manufacturing, Ltd. | Toric intraocular lens material |
| ATE206314T1 (de) | 1998-04-15 | 2001-10-15 | Alcon Lab Inc | Beschichtungszusammensetzung für intraocularen linsen |
| US6455318B1 (en) | 1998-04-15 | 2002-09-24 | Alcon Manufacturing, Ltd. | Collagen IV adhesion assay for intraocular lens materials |
| US6482230B1 (en) | 1998-04-15 | 2002-11-19 | Alcon Manufacturing, Ltd. | Lens epithelial cell growth assay for intraocular lens materials |
| CA2317757C (en) * | 1998-04-15 | 2008-03-25 | Alcon Laboratories, Inc. | Bicomposite intraocular lens and method for its preparation |
| SE0402272D0 (sv) | 2004-09-21 | 2004-09-21 | Amo Groningen Bv | Methods of treating a body site with a viscoelastic preparation |
| EP1791523B1 (de) * | 2004-09-21 | 2013-10-23 | AMO Groningen B.V. | Methode zur herstellung einer viskoelastischen lösung |
| WO2014153394A1 (en) * | 2013-03-21 | 2014-09-25 | Genisphere, Llc | Cellular delivery of dna intercalating agents |
| EP3416671A4 (de) | 2016-02-19 | 2019-10-30 | Genisphere, LLC | Nukleinsäureträger und therapeutische verfahren zur verwendung |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2014244A1 (en) * | 1989-04-13 | 1990-10-13 | Takeda Chemical Industries, Ltd. | Stabilized composition of anthracyclines |
-
1995
- 1995-05-05 SE SE9501671A patent/SE9501671D0/xx unknown
-
1996
- 1996-05-03 AU AU57840/96A patent/AU5784096A/en not_active Abandoned
- 1996-05-03 EP EP96914498A patent/EP0825877B1/de not_active Expired - Lifetime
- 1996-05-03 AT AT96914498T patent/ATE285252T1/de not_active IP Right Cessation
- 1996-05-03 WO PCT/SE1996/000588 patent/WO1996034629A1/en not_active Ceased
- 1996-05-03 DE DE69634080T patent/DE69634080T2/de not_active Expired - Lifetime
- 1996-05-03 JP JP8533247A patent/JPH11504342A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11504342A (ja) | 1999-04-20 |
| ATE285252T1 (de) | 2005-01-15 |
| EP0825877A1 (de) | 1998-03-04 |
| EP0825877B1 (de) | 2004-12-22 |
| DE69634080D1 (de) | 2005-01-27 |
| WO1996034629A1 (en) | 1996-11-07 |
| AU5784096A (en) | 1996-11-21 |
| DE69634080T2 (de) | 2006-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA29563C2 (uk) | Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду | |
| YU13695A (sh) | Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije | |
| NZ314442A (en) | Extended release formulation comprising venlafaxine hydrochloride, film coating composition | |
| ATE216241T1 (de) | Sehr niedrigdosiertes orales kontrazeptiv mit weniger menstruationsblutungen und verzögerter wirkung | |
| IL109800A (en) | Sustained release drug formulation containing a tramadol salt comprising cellulose ether and/or cellulose ester having a viscosity between 3,000 and 150,000 mPas | |
| BG104476A (en) | Therapeutical form for tolterodin with controlled release | |
| MX9700850A (es) | Formulaciones y metodos para proporcionar anestesia local prolongada. | |
| GEP20012549B (en) | Pharmaceutical Composition Containing Sumatriptan | |
| IL96900A0 (en) | Pharmaceutical composition containing naproxen | |
| AU4121297A (en) | Galenic form with extended release of milnacipran | |
| AU6136199A (en) | Dosage form comprising therapeutic formulation | |
| GR3036798T3 (en) | Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules | |
| MEP36008A (hr) | Farmaceutska kombinacija etinilestradiola i drospirenona za primjenu kao kontraceptivnog sredstva | |
| ATE198152T1 (de) | Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe | |
| MY130098A (en) | Local drug delivery film for periodontal treatment | |
| EP0866656A4 (de) | Inhibierung des alpha tumornekrose-faktors | |
| SE9501671D0 (sv) | Method and composition for prevention of posterior capsule opacification | |
| MY124465A (en) | Reduction of infarct volume using citicoline | |
| BG105570A (en) | Pharmaceutical compositions for modified release insulin sensitiser | |
| PL317996A1 (en) | Carbamazepinic form of a drug with retarded release of biologically active substance | |
| KR960703593A (ko) | (R)-암로디핀에 의한 평활근 세포 이동의 억제 (Inhibition of Smooth Muscle Cell Migration by (R)-Amlodipine) | |
| GEP20043377B (en) | Pharmaceutical Complex | |
| EP0743068A3 (de) | Zusammensetzung zur Hemmung von Knochenverlust welche Vanadylsulfat enthält | |
| GB9420748D0 (en) | 1,5 benzodiazepine derivatives | |
| MY114610A (en) | Controlled drug delivery system for diltiazem. |